Department of Urology, Andrology and Renal Transplantation, University Hospital of Besançon, 3, boulevard Fleming, 25000 Besançon, France; University of Franche-Comté, 25000 Besançon, France.
Department of Urology, Andrology and Renal Transplantation, University Hospital of Besançon, 3, boulevard Fleming, 25000 Besançon, France.
Prog Urol. 2022 Jul;32(8-9):577-584. doi: 10.1016/j.purol.2022.03.002. Epub 2022 May 3.
Several studies have reported blood transfusion were associated with a decrease of survival after oncological surgery. For kidney cancer, the effect of blood transfusion is still debated. The objective of this study was to determine the effect of blood transfusion after oncological nephrectomy on overall, specific and recurrence-free survival in a retrospective cohort of localized or locally advanced kidney cancer.
We performed a monocentric retrospective analysis of all patients managed by surgery for localized or locally advanced renal cancer between January 2000 and December 2016. We compared overall and specific survival and recurrence-free survival between two groups: patients transfused and not transfused. Demographic, surgical and tumor characteristics were compared. Survival analyses were performed using univariate Cox regression and multivariate Cox proportional regression test.
We included 382 patients in this study: 320 (83.8%) were not transfused and 62 (16.2%) were transfused. Transfused patients were significantly older (P=0.001) and had a lower pre-operative hemoglobin level (P=0.008). Operative and oncological characteristics were also different between both groups. In univariate analysis, we showed that blood transfusion was associated with lower overall survival (P<0.001), specific survival (P<0.001), and recurrence-free survival (P<0.001). In multivariate analysis, we found that blood transfusion was not associated with overall survival, or specific survival, but it was associated with lower recurrence-free survival (HR: 1.967, CI95% [1.024-3.780], P=0.042).
Perioperative blood transfusion is an independent risk factor that increases tumor recurrence among patients treated with nephrectomy for renal cancer.
多项研究报告称,输血与肿瘤手术后的生存率降低有关。对于肾癌,输血的影响仍存在争议。本研究的目的是确定在局部或局部进展性肾癌的回顾性队列中,肿瘤切除术术后输血对总生存率、特定生存率和无复发生存率的影响。
我们对 2000 年 1 月至 2016 年 12 月期间接受手术治疗的局部或局部进展性肾癌患者进行了单中心回顾性分析。我们比较了输血组和未输血组的总生存率、特定生存率和无复发生存率。比较了人口统计学、手术和肿瘤特征。使用单因素 Cox 回归和多因素 Cox 比例风险回归检验进行生存分析。
本研究共纳入 382 例患者:320 例(83.8%)未输血,62 例(16.2%)输血。输血组患者年龄明显较大(P=0.001),术前血红蛋白水平较低(P=0.008)。两组患者的手术和肿瘤特征也存在差异。单因素分析显示,输血与总生存率(P<0.001)、特定生存率(P<0.001)和无复发生存率(P<0.001)降低相关。多因素分析显示,输血与总生存率或特定生存率无关,但与无复发生存率降低相关(HR:1.967,95%CI[1.024-3.780],P=0.042)。
围手术期输血是肾细胞癌患者肾切除术治疗后肿瘤复发的独立危险因素。